Michael H Muders
Overview
Explore the profile of Michael H Muders including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
1161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vosbeck K, Forster S, Mayr T, Sahu A, Haddouti E, Al-Adilee O, et al.
Cancers (Basel)
. 2024 May;
16(10).
PMID: 38792002
Bone marrow fibrosis in myeloproliferative neoplasm (MPN), myelodysplastic syndromes (MDS), MPN/MDS overlap syndromes and acute myeloid leukemia (AML) is associated with poor prognosis and early treatment failure. Myelofibrosis (MF) is...
2.
Westphal D, Meinhardt M, Grutzmann K, Schone L, Steininger J, Neuhaus L, et al.
J Invest Dermatol
. 2023 Jan;
143(7):1233-1245.e17.
PMID: 36716920
Despite remarkable advances in treating patients with metastatic melanoma, the management of melanoma brain metastases remains challenging. Recent evidence suggests that epigenetic reprogramming is an important mechanism for the adaptation...
3.
Islam R, Mishra J, Polavaram N, Bhattacharya S, Hong Z, Bodas S, et al.
Cell Rep
. 2022 Jul;
40(3):111097.
PMID: 35858551
Neuroendocrine (NE)-like tumors secrete various signaling molecules to establish paracrine communication within the tumor milieu and to create a therapy-resistant environment. It is important to identify molecular mediators that regulate...
4.
Dutta S, Polavaram N, Islam R, Bhattacharya S, Bodas S, Mayr T, et al.
Oncogene
. 2022 Jun;
41(30):3747-3760.
PMID: 35754042
Aberrant transcriptional activity of androgen receptor (AR) is one of the dominant mechanisms for developing of castration-resistant prostate cancer (CRPC). Analyzing AR-transcriptional complex related to CRPC is therefore important towards...
5.
Simon A, Esser L, Ellinger J, Ritter M, Kristiansen G, Muders M, et al.
Front Oncol
. 2022 Jun;
12:883195.
PMID: 35646693
The treatment of advanced renal cell carcinoma remains a challenge. To develop novel therapeutic approaches, primary cell cultures as an model are considered more representative than commercial cell lines. In...
6.
Strigli A, Gopalakrishnan S, Zeissig Y, Basic M, Wang J, Schwerd T, et al.
Sci Immunol
. 2021 Nov;
6(65):eabf7473.
PMID: 34739342
Inflammatory bowel disease (IBD) is characterized by inappropriate immune responses to the microbiota in genetically susceptible hosts, but little is known about the pathways that link individual genetic alterations to...
7.
Niu Y, Mayr T, Muders M
Signal Transduct Target Ther
. 2021 Jul;
6(1):279.
PMID: 34285185
No abstract available.
8.
Polavaram N, Dutta S, Islam R, Bag A, Roy S, Poitz D, et al.
Bone Res
. 2021 May;
9(1):24.
PMID: 33990538
Understanding the role of neuropilin 2 (NRP2) in prostate cancer cells as well as in the bone microenvironment is pivotal in the development of an effective targeted therapy for the...
9.
Forster S, Givehchi M, Nitschke K, Mayr T, Kilian K, Dutta S, et al.
Genes (Basel)
. 2021 Apr;
12(4).
PMID: 33918816
Urothelial bladder cancer ranks among the 10 most frequently diagnosed cancers worldwide. In our previous study, the transmembrane protein neuropilin-2 (NRP2) emerged as a predictive marker in patients with bladder...
10.
Betzler A, Nanduri L, Hissa B, Blickensdorfer L, Muders M, Roy J, et al.
Cancers (Basel)
. 2021 Mar;
13(4).
PMID: 33671932
Background: Colorectal cancer (CRC) development is a multi-step process resulting in the accumulation of genetic alterations. Despite its high incidence, there are currently no mouse models that accurately recapitulate this...